We found a novel polymorphism, −66T/C, in the promoter region of human FcεRIα, the specific component of the high affinity receptor for IgE (FcεRI), which is essential for the cell surface expression of FcεRI and the binding of IgE Ab. When the effect of the single nucleotide replacement on the promoter function was analyzed, the transcription activity of the T allele promoter was found to be higher than that of the C allele promoter, and was markedly up-regulated by the overexpression of GATA-1 when compared with the C allele promoter. This is probably because the promoter with T at −66 has an additional GATA-1-binding motif in the region, which may assure higher affinity of the transcription factor to the promoter. In accordance with this, EMSA actually indicated that GATA-1 bound to the T allele probe (−80/−59) with the affinity higher than that to the C allele probe. Statistical analysis suggested that a significant portion of nonallergic individuals has heterozygous −66T/C genotype, while most of allergic individuals have homozygous −66T/T genotype in Japanese population. Our findings for the first time demonstrate the presence of FcεRIα polymorphism related to the allergic diseases.
Transcriptional regulation of the gene-encoding human FcεRI α-chain was analyzed in detail. EMSA revealed that either YY1 or PU.1 bound to the region close to that recognized by Elf-1. The α-chain promoter activity was up-regulated ∼2-fold by exogenously expressed YY1 or PU.1 and ∼7-fold by GATA-1, respectively, in KU812 cells. In contrast, coexpression of GATA-1 with either of PU.1 or YY1 dramatically activated the promoter ∼41- or ∼27-fold, respectively. Especially synergic activation by GATA-1 and PU.1 was surprising, because these transcription factors are known to inhibit the respective transactivating activities of each other. These up-regulating effects of PU.1 and YY1 with GATA-1 were inhibited by overexpression of Elf-1, indicating that Elf-1 serves as a repressor for the α-chain gene expression. Transcriptional regulation of the α-chain gene through four transcriptional factors is discussed.
The FcR β-chain, a subunit of two related multisubunit receptor complexes, the FcεRI and FcγRIII, amplifies the mast cell response and is necessary for the cell surface expression of FcεRI in mouse. The transient reporter assay indicated that −69/+4 region is required for cell type-specific transcriptional regulation of mouse β-chain gene. EMSA using Abs against transcription factors or competitive oligonucleotides demonstrated that −58/−40 region (containing overlapping three GATA-1 sites, −53/−48, −46/−51, and −42/−47) and −31/−26 region (containing one GATA-1 site) are recognized by GATA-1. The promoter activity of β-chain was decreased by nucleotide replacements of the GATA-1 sites in mouse mast cell line PT18. Furthermore, exogenously produced GATA-1 up-regulated the promoter activity in CV-1 cells, which are negative in the β-chain production and the up-regulation was apparently suppressed by GATA-1 site mutations. These results indicate that cell type-specific transcription of mouse β-chain gene is regulated by GATA-1.
The β subunit of the high-affinity IgE receptor (FcεRI) plays an important role in IgE-mediated allergic reactions as an amplifier for cell surface expression and signal transduction of FcεRI. FcεRIβ is presumed to be one of the genes linked with atopic diseases. However, the validity of the associations previously found between single nucleotide polymorphisms (SNPs) in FcεRIβ and atopic diseases is questionable. In the present study, we found correlation between the SNP of FcεRIβ at +6960A/G, resulting in a Glu237Gly amino acid substitution, and the cell surface expression level of FcεRI on blood basophils, although it has been shown that the Glu237Gly mutation itself does not affect the surface expression or function of FcεRI. We additionally found four SNPs in the promoter region of FcεRIβ, among which −426T/C and −654C/T were tightly linked with +6960A/G. Reporter plasmids carrying the −426C and −654T promoter displayed higher transcriptional activity than those carrying the −426T and −654C promoter. We found that transcription factor YY1 preferentially bound and transactivated the −654T promoter. Furthermore, expression of FcεRI β-chain mRNA in basophils from individuals who have the minor heterozygous genotype was significantly higher than that of the major homozygous genotype. These results suggest that the SNPs in the FcεRIβ promoter are causally linked with atopy via regulation of FcεRI expression.
PU.1 is a myeloid- and lymphoid-specific transcription factor that belongs to the Ets family. Recently, we found that overproduction of PU.1 in mouse bone marrow-derived hemopoietic progenitor cells induced monocyte-specific gene expression and caused their monocyte-like morphological change. In the present study, PU.1 was overproduced by using retrovirus expression system in differentiated bone marrow-derived mast cells. By overexpression of PU.1, cell surface expression of MHC class II, CD11b, CD11c, and F4/80 was induced, accompanied by reduced expression of c-kit, a mast cell-specific marker. Morphology of PU.1-transfected cells was altered toward monocyte-like one. PU.1-overproducing cells acquired T cell stimulatory ability and showed an increase in response to LPS stimulation, while response through FcεRI was markedly reduced by overproduction of PU.1. These results suggest that the differentiated mast cells still have potential to display monocytic features. When PU.1 was overproduced in a different type of mast cell, peritoneal mast cells, similar monocyte-like morphological change, and the expression of CD11b and F4/80 were induced. However, surface level of CD11c and MHC class II was not affected. These results indicate that the potential capacity to exhibit monocytic features is different between both the mast cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.